BIDEN'S FDA PICK IN TROUBLE AS SOME REPUBLICANS AND DEMOCRATS PULL SUPPORT — President Joe Biden's nominee to lead FDA does not yet have the votes in the Senate needed to give the agency its first political leader in more than a year, David Lim, Lauren Gardner and Adam Cancryn report. A handful of Democratic defections over former FDA Commissioner Robert Califf's track record on opioids and a new GOP push to kill his nomination have sparked deep frustration among top Democrats and touched off a round of finger pointing, with Califf allies privately blaming the White House for doing too little to shore up support for its own nominee. "If the vote were held today, he would not have the votes," said one person with knowledge of the matter. CLEAN UP CREW: In recent weeks, Senate HELP Chair Sen. Patty Murray (D-WA) and ranking member Sen. Richard Burr (R-NC) have worked to round up last-minute support for Califf, in hopes of a floor vote by early February. The White House is also dispatching senior aides like chief medical adviser Anthony Fauci, Covid-19 coordinator Jeff Zients and White House staff secretary Neera Tanden to make calls on Califf's behalf. "We are confident Dr. Califf will be confirmed with bipartisan support, and it is critical to have confirmed leadership at the FDA in the midst of a pandemic," White House spokesperson Chris Meagher said. PROGRESSIVES DEMAND BBB PASSAGE BEFORE MARCH — With negotiations on a new version of Democrats' social spending bill stalled since Sen. Joe Manchin (D-WV) withdrew his support at the end of 2021, Congressional Progressive Caucus chair Rep. Pramila Jayapal (D-WA) laid down a new marker Thursday in a meeting with the group Evergreen Action: pass a few key pieces of Build Back Better in the next few months and then work on the rest. "We are calling for President Biden and Senate Democrats to pass the Build Back Better Act by March 1, so the President can use the power of the State of the Union platform to share with the nation the relief that people will soon receive," she said in a statement after the meeting. Jayapal says she recently spoke with Manchin about the areas of agreement that could go in the first tranche: $550 billion on climate change, universal pre-K, eldercare, child care, lowering prescription drug costs and housing provisions. While President Biden recently endorsed the strategy of passing his agenda in smaller pieces, it risks leaving behind major health care provisions like closing the Medicaid gap and extending Obamacare subsidies that are set to expire at the end of the year. As for Jayapal's timeline, some top aides are skeptical. "Setting arbitrary deadlines clearly didn't work last year," a senior Senate Democratic aide told PULSE. "We're still having discussions about what can get 50 votes." The pharmaceutical industry, however, is taking the call to action seriously. On Friday, PhRMA is launching a seven-figure national ad campaign that will run in digital, print, radio and TV outlets blasting the drug price reforms included in Build Back Better as "government price setting" that will "risk access to medicines and future cures." The group's spokesperson, Sarah Sutton, said in a statement to PULSE that the ads' goal is "reminding policymakers of some of the real dangers of" the package the House passed last year that would allow Medicare to negotiate the prices of some drugs, cap price hikes at the rate of inflation and more. "We think there's a better way that brings real relief to patients without jeopardizing access to medicines and future innovation," she said. Democrats have long cited Big Pharma's opposition to the bill and its influence in Washington as one of the biggest hurdles standing in the way of its passage.
|
Comments
Post a Comment